Menu
The British Private Equity and Venture Capital Association (BVCA) Vision 2025 Awards are a celebration of the success that private equity and venture capital-backed companies bring to the UK economy. These businesses are catalysts for innovation, economic growth, and job creation. The awards shine a light on exceptional accomplishments across sectors, giving well-deserved recognition to companies transforming their industries.
This year, the awards took place on Thursday, May 22, at the iconic Merchant Hotel in Belfast. Not only did the evening celebrate exceptional businesses, but it also launched the latest BVCA report, Private Capital in Northern Ireland. The report highlights the crucial role of private equity-backed businesses, which contribute £3 billion annually to Northern Ireland’s economy and support over 47,000 jobs.
Neurovalens, a groundbreaking medical device company based in Belfast, earned recognition in the Early Stage category at the awards. Known for developing non-invasive neurostimulation treatments for chronic conditions, such as insomnia, Neurovalens has positioned itself as a leader in innovative healthcare solutions.
The company’s signature technology, Modius, delivers non-invasive electrical stimulation that targets key neural pathways. This revolutionary approach demonstrates how Neurovalens is transforming treatment paradigms for chronic health conditions. Their selection as the Early Stage winner underscores their potential to revolutionise healthcare, making treatments more accessible and less invasive.
The awards dinner was attended by key Neurovalens representatives, including Chief Technology Officer Chris McCabe and Chief Regulatory Officer Sinead Watson. Adding further to the evening, Sinead Watson took the stage as part of a highly regarded forum discussion panel at the event, showcasing Neurovalens’ thought leadership in the medical technology sector.
Dr. Jason McKeown, CEO of Neurovalens, shared his gratitude, saying, “We’re honored to receive this recognition from the BVCA. This award highlights the impact that strategic investment and a strong partnership can have on early-stage companies in Northern Ireland.”
Dr. McKeown added, “At Neurovalens, our goal is to transform how chronic health conditions are treated. This recognition represents the progress we’ve made and inspires us to continue our work in making non-invasive neurostimulation treatments more widely available.”
Moments like these don’t happen in isolation. Neurovalens’ success would not be possible without the dedicated efforts of its talented team, the support of its investors, and the encouragement of its broader community.
Special thanks go to BVCA for organising such a meaningful event and highlighting the impact of private equity and venture capital across the UK. A heartfelt thank you also goes to IQ Capital, whose investment and belief in Neurovalens’ vision have been instrumental in the company’s remarkable growth thus far.
Finally, congratulations are in order for all the Neurovalens team who work tirelessly toward creating innovative health solutions that change lives for the better. This victory is a reflection of your dedication and expertise.
Keep up to date with our latest products, research and company news.
Neurovalens is a global health-tech company that creates non-invasive neurostimulation products used to solve some of the world’s greatest health challenges.
Our medical device technology offers unparalleled transdermal activation of the homeostatic nuclei of the brainstem and hypothalamus, allowing for alterations in autonomic function, circadian regulation and Neuro-metabolic influence.
